Collaboration award for Dundee PROTAC drug discovery project
A research team at the University of Dundee have been recognised for their work with industry partner, Boehringer Ingelheim, with the Biochemical Society’s 2026 Industry and Academic Collaboration Award.
The award ‘recognises and promotes an outstanding individual or team who has made an inspirational contribution to the biosciences and to industry-academia interaction’.
The award was given to Professor Alessio Ciulli, of the University’s Centre for Targeted Protein Degradation (CeTPD), and members of its ACBI (Alessio Ciulli and Boehringer Ingelheim) PROTAC collaboration team.
The group is working with Boehringer Ingelheim on the development of proteolysis targeting chimaeras (PROTACs).
Professor Ciulli said: “I am delighted to receive this award on behalf of the entire ACBI team. It recognises the vision and success of our ‘team science’ with Boehringer Ingelheim. The collaboration has demonstrated the power of our approach to rationally design PROTACs. It has achieved tremendous impact, with highly cited papers, and through openly sharing with the research community our best-quality molecules, as these continue to be developed toward new medicines for cancer patients.
“This prestigious award is a tribute to the hard work and dedication of all scientists at Dundee and Boehringer that have worked together to degrade high-profile cancer targets such as KRAS and SMARCA2.”
“This award is a great recognition of our collaboration,” added Peter Ettmayer, Head of Drug Discovery Sciences Vienna at Boehringer Ingelheim. “We are very proud of our continuing partnership with Alessio Ciulli, which began in 2016, right at the outset of a new field that is now known as targeted protein degradation. It has since been one of the longest and largest collaborations ever pursued by Boehringer with a single PI-led academic laboratory.”
Diana Spencer, Senior Digital Content Editor, DDW
